Giant Food gets in the NASCAR groove with pop-up store
LANDOVER, Md. NASCAR fans shopping for tailgating items can look no further than a new Giant Food on-site, pop-up store at the Dover International Speedway.
The 5,000-sq.-ft. store will offer 2,500 items for fans attending the “Sunoco 150” NASCAR K&N Pro Series East, Saturday’s 200-mile NASCAR Nationwide Series, and the “AAA 400” NASCAR Sprint Cup Series races in Dover, Del.
“In little more than a week, we’ve been able to build an impressive but temporary Giant store. I’m incredibly proud of the teamwork of all departments [that] have worked hard to ensure that our store is ready for speedway shoppers,” said Rob Harman, VP operations for Giant Food of Landover, Md. “We’re very excited to welcome thousands of NASCAR fans here in Dover and look forward to a successful and exciting race weekend.”
BI commences late-stage clinical trial for breast cancer treatment
INGELHEIM, Germany Boehringer Ingelheim has started a late-stage clinical trial of a drug for treating breast cancer, the German drug maker said Friday.
The phase 3 trial, dubbed the “LUX-Breast 1” trial, will evaluate the drug afatinib in patients with advanced breast cancer. The drug is a tablet that BI said was the first to inhibit two chemicals involved in tumor growth — the epidermal growth factor receptor, or EGFR, and the human epidermal receptor, also known as HER2.
“We have seen positive results in our proof-of-concept studies for afatinib in breast cancer, and are glad to advance the program into pivotal phase 3,” BI corporate SVP medicine Klaus Dugi said. “We are delighted to be able to initiate this important trial together with a range of leading investigators to assess the value of afatinib for women with advanced breast cancer.”
Emergent to develop anthrax vaccine on HHS’ behalf
WASHINGTON Emergent BioSolutions has landed a $51 million contract from the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to develop a new anthrax vaccine.
In the first two years of the contract, Emergent will develop the final vaccine formulation and test its stability. HHS said it can extend the contract annually for up to three years to support scale-up and optimization for large-scale manufacturing, as well as additional animal studies needed to apply for Food and Drug Administration approval of the vaccine.
If the government extends the contract for all three years, the total five-year contract value could be $186.6 million.